Fund shareholders of Karyopharm Therapeutics Inc
ISIN US48576U2050 · United States · LEI 549300J1VANRCNTYST87
- Fund shareholders
- 22
- Of which ETFs
- 3 19 other funds
- Value held
- 11.7M $
- Share of capital
- 8.7 % of 22.7M shares on Aug 6, 2026
- Sold short
- 0.5 % by 1 fund, as of Aug 20, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Value Fund, Inc. T. ROWE PRICE SMALL-CAP VALUE FUND, INC. | 876,504 | 4.9M $ | 0.05 % | 3.86 % | as of Mar 31, 2026 ↗ |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 509,129 | 2.8M $ | 0.00 % | 2.24 % | as of Mar 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 215,082 | 1.2M $ | 0.00 % | 0.95 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 90,084 | 847.7K $ | 0.00 % | 0.40 % | as of Feb 28, 2026 ↗ |
| Ultra-Small Company Fund Bridgeway Funds, Inc. | 49,873 | 277.8K $ | 0.33 % | 0.22 % | as of Mar 31, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 42,667 | 237.7K $ | 0.02 % | 0.19 % | as of Mar 31, 2026 ↗ |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 33,333 | 185.7K $ | 0.03 % | 0.15 % | as of Mar 31, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 30,230 | 284.5K $ | 0.00 % | 0.13 % | as of Feb 28, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 23,866 | 224.6K $ | 0.00 % | 0.11 % | as of Feb 28, 2026 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 22,000 | 122.5K $ | 0.10 % | 0.10 % | as of Mar 31, 2026 ↗ |
| Invesco RAFI US 1500 Small-Mid ETF Invesco Exchange-Traded Fund Trust | 16,729 | 139K $ | 0.00 % | 0.07 % | as of Apr 30, 2026 ↗ |
| Schwab Total Stock Market Index Fund SCHWAB CAPITAL TRUST | 13,400 | 111.4K $ | 0.00 % | 0.06 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Extended Equity Market Index Fund T. ROWE PRICE INDEX TRUST, INC. | 10,886 | 60.6K $ | 0.01 % | 0.05 % | as of Mar 31, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 10,033 | 94.4K $ | 0.00 % | 0.04 % | as of Feb 28, 2026 ↗ |
| VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS | 10,021 | 55.8K $ | 0.00 % | 0.04 % | as of Mar 31, 2026 ↗ |
| TIFF MULTI-ASSET FUND TIFF Investment Program | 5,758 | 32.1K $ | 0.00 % | 0.03 % | as of Mar 31, 2026 ↗ |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 5,513 | 30.7K $ | 0.00 % | 0.02 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Health Care ETF T. Rowe Price Exchange-Traded Funds, Inc. | 4,484 | 25K $ | 0.12 % | 0.02 % | as of Mar 31, 2026 ↗ |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 3,002 | 16.7K $ | 0.01 % | 0.01 % | as of Mar 31, 2026 ↗ |
| Diversified Equity Master Portfolio Master Investment Portfolio | 1,476 | 8.2K $ | 0.00 % | 0.01 % | as of Mar 31, 2026 ↗ |
| Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds | 1,467 | 8.2K $ | 0.00 % | 0.01 % | as of Mar 31, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 97 | 803.9 $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Ultra-Small Company Fund Bridgeway Funds, Inc. | 0.33 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Health Care ETF T. Rowe Price Exchange-Traded Funds, Inc. | 0.12 % | as of Mar 31, 2026 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 0.10 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Small-Cap Value Fund, Inc. T. ROWE PRICE SMALL-CAP VALUE FUND, INC. | 0.05 % | as of Mar 31, 2026 ↗ |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 0.03 % | as of Mar 31, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 0.02 % | as of Mar 31, 2026 ↗ |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 0.01 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Extended Equity Market Index Fund T. ROWE PRICE INDEX TRUST, INC. | 0.01 % | as of Mar 31, 2026 ↗ |
| Invesco RAFI US 1500 Small-Mid ETF Invesco Exchange-Traded Fund Trust | 0.00 % | as of Apr 30, 2026 ↗ |
| TIFF MULTI-ASSET FUND TIFF Investment Program | 0.00 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 22 | +1 | 1,975,634 | +24.7 % |
| 2026Q1 | 21 | 0 | 1,583,833 | +63.1 % |
| 2025Q4 | 21 | -3 | 971,016 | -19.3 % |
| 2025Q3 | 24 | -4 | 1,203,817 | +47.3 % |
| 2025Q2 | 28 | 817,267 |
Short sellers of Karyopharm Therapeutics Inc
Regulators publish the open short positions in this company. Titelia read them from quivad on Aug 20, 2026: today's figure
| Seller | Position | Disclosed on |
|---|---|---|
| Squarepoint Ops LLC | 0.5 % | May 13, 2025 |
Institutional managers
73 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| Commodore Capital LP | 1,950,000 | 10.9M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 1,917,354 | 10.7M $ | as of Mar 31, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,806,322 | 10.1M $ | as of Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 1,542,090 | 8.6K $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 947,579 | 5.3M $ | as of Mar 31, 2026 |
| Catalio Capital Management, LP | 897,709 | 5M $ | as of Mar 31, 2026 |
| Ikarian Capital, LLC | 733,435 | 4.1M $ | as of Mar 31, 2026 |
| Affinity Asset Advisors, LLC | 500,000 | 2.8M $ | as of Mar 31, 2026 |
| Avidity Partners Management LP | 463,741 | 2.6M $ | as of Mar 31, 2026 |
| Soleus Capital Management, L.P. | 440,000 | 2.5M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 420,571 | 2.3M $ | as of Mar 31, 2026 |
| Boxer Capital Management, LLC | 302,536 | 1.7M $ | as of Mar 31, 2026 |
| Davidson Kempner Capital Management LP | 300,000 | 1.7M $ | as of Mar 31, 2026 |
| ACORN CAPITAL ADVISORS, LLC | 287,826 | 1.6M $ | as of Mar 31, 2026 |
| Eversept Partners, LP | 276,174 | 1.5M $ | as of Mar 31, 2026 |
| Jump Financial, LLC | 262,146 | 1.5M $ | as of Mar 31, 2026 |
| Trexquant Investment LP | 257,903 | 1.4M $ | as of Mar 31, 2026 |
| ACADIAN ASSET MANAGEMENT LLC | 248,957 | 1.4K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 244,899 | 1.4M $ | as of Mar 31, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 213,810 | 1.2M $ | as of Mar 31, 2026 |
| Brevan Howard Capital Management LP | 212,367 | 1.2M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 206,133 | 1.1M $ | as of Mar 31, 2026 |
| UBS Group AG | 194,017 | 1.1M $ | as of Mar 31, 2026 |
| GROUP ONE TRADING LLC | 191,527 | 1.1M $ | as of Mar 31, 2026 |
| XTX Topco Ltd | 164,443 | 915.9K $ | as of Mar 31, 2026 |
Declared shareholders of Karyopharm Therapeutics Inc
There are 10 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Commodore Capital LP and 3 others | 9.90 % | 1,950,000 | as of Mar 26, 2026 · SCHEDULE 13G |
| RA Capital Management, L.P. and 3 others | 9.90 % | 2,078,913 | as of Mar 26, 2026 · SCHEDULE 13G |
| Affinity Asset Advisors, LLC and 1 other | 8.60 % | 2,073,517 | as of Mar 31, 2026 · SCHEDULE 13G |
| Adage Capital Management, L.P. and 2 others | 8.08 % | 1,821,736 | as of Mar 31, 2026 · SCHEDULE 13G |
| ACORN BIOVENTURES, L.P. and 4 others | 6.70 % | 1,518,113 | as of May 13, 2026 · SCHEDULE 13G |
| T. Rowe Price Investment Management, Inc. | 6.60 % | 1,539,147 | as of May 31, 2026 · SCHEDULE 13G |
| THE GOLDMAN SACHS GROUP, INC. and 1 other | 5.10 % | 991,364 | as of Mar 31, 2026 · SCHEDULE 13G |
| Opaleye Management Inc. and 2 others | 2.67 % | 619,089 | as of Mar 31, 2026 · SCHEDULE 13G |
| Integrated Core Strategies (US) LLC and 3 others | 2.30 % | 511,571 | as of Mar 31, 2026 · SCHEDULE 13G |
| Ikarian Capital, LLC and 1 other | 0.00 % | 0 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of Karyopharm Therapeutics Inc". https://titelia.com/en/stocks/karyopharm-therapeutics-inc-US48576U2050